Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied Dna Scns (NQ: APDN )

0.9486 -0.0014 (-0.15%)
Streaming Delayed Price Updated: 2:22 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Applied Dna Scns

< Previous 1 2 3 4 Next >
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
Via ACCESSWIRE
Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)
Via ACCESSWIRE
Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform
Via ACCESSWIRE
Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
Via ACCESSWIRE
Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs
Via ACCESSWIRE
Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit
Via ACCESSWIRE
Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Applied DNA Reports Second Quarter Fiscal 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production
Via ACCESSWIRE
Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023
Via ACCESSWIRE
Applied DNA Biotherapeutics Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences
Via ACCESSWIRE
Applied DNA Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT(TM) Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach
Via ACCESSWIRE
Applied DNA Announces Presentation at Upcoming Healthcare Investor Conference
Via ACCESSWIRE
Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA's CertainT® Supply Chain Traceability Platform Featured in New York Times Article About the Need for Transparency and Compliance in Global Supply Chains Under Recently Passed U.S. Federal Regulation
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Achieves Milestone for Large-Scale linearDNA™ Production, Delivers Largest Single Shipment by Volume to Date
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Submits Validation Package to New York State Department of Health for Approval of Pharmacogenomic (PGx) Assay
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Announces New York State Award Valued at Up To $1.5 Million to Support Establishment of cGMP linearDNA™ Production Capacity on Long Island, New York
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Reports First Quarter Fiscal 2023 Financial Results
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA to Report First Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, February 9, 2023
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Announces Fourth Quarter and Fiscal Year 2022 Financial Results
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA to Report Fiscal 2022 Fourth Quarter and Year End Financial Results on December 14, 2022
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA to Establish North America’s First Enzymatic (Cell Free) Large-Scale cGMP DNA Manufacturing Capacity in Suffolk County, New York
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Sciences (NASDAQ: APDN) Receives Largest Purchase Order for LinearDNA Valued Over Mid-Six-Figures
Applied DNA Sciences, Inc. (NASDAQ: APDN) is engaged as a biotechnology company, which is focused on developing PCR-based DNA technologies. 
Via Spotlight Growth
Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA’s Biotherapeutics Subsidiary Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022
From Applied DNA Sciences, Inc.
Via Business Wire
Applied DNA Launches Monkeypox Testing Service
From Applied DNA Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.